Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Characterization of TEM1/endosialinin human and murine brain tumors

Authors: Eleanor B Carson-Walter, Bethany N Winans, Melissa C Whiteman, Yang Liu, Sally Jarvela, Hannu Haapasalo, Betty M Tyler, David L Huso, Mahlon D Johnson, Kevin A Walter

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

TEM1/endosialin is an emerging microvascular marker of tumor angiogenesis. We characterized the expression pattern of TEM1/endosialin in astrocytic and metastatic brain tumors and investigated its role as a therapeutic target in human endothelial cells and mouse xenograft models.

Methods

In situ hybridization (ISH), immunohistochemistry (IH) and immunofluorescence (IF) were used to localize TEM1/endosialin expression in grade II-IV astrocytomas and metastatic brain tumors on tissue microarrays. Changes in TEM1/endosialin expression in response to pro-angiogenic conditions were assessed in human endothelial cells grown in vitro. Intracranial U87MG glioblastoma (GBM) xenografts were analyzed in nude TEM1/endosialin knockout (KO) and wildtype (WT) mice.

Results

TEM1/endosialin was upregulated in primary and metastatic human brain tumors, where it localized primarily to the tumor vasculature and a subset of tumor stromal cells. Analysis of 275 arrayed grade II-IV astrocytomas demonstrated TEM1/endosialin expression in 79% of tumors. Robust TEM1/endosialin expression occurred in 31% of glioblastomas (grade IV astroctyomas). TEM1/endosialin expression was inversely correlated with patient age. TEM1/endosialin showed limited co-localization with CD31, αSMA and fibronectin in clinical specimens. In vitro, TEM1/endosialin was upregulated in human endothelial cells cultured in matrigel. Vascular Tem1/endosialin was induced in intracranial U87MG GBM xenografts grown in mice. Tem1/endosialin KO vs WT mice demonstrated equivalent survival and tumor growth when implanted with intracranial GBM xenografts, although Tem1/endosialin KO tumors were significantly more vascular than the WT counterparts.

Conclusion

TEM1/endosialin was induced in the vasculature of high-grade brain tumors where its expression was inversely correlated with patient age. Although lack of TEM1/endosialin did not suppress growth of intracranial GBM xenografts, it did increase tumor vascularity. The cellular localization of TEM1/endosialin and its expression profile in primary and metastatic brain tumors support efforts to therapeutically target this protein, potentially via antibody mediated drug delivery strategies.
Appendix
Available only for authorised users
Literature
1.
Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, Dufault MR, Zhang X, Zhang W, Walter-Yohrling J, et al: Vascular gene expression in nonneoplastic and malignant brain. The American journal of pathology. 2004, 165 (2): 601-608.CrossRefPubMedPubMedCentral
2.
St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, et al: Genes expressed in human tumor endothelium. Science (New York, NY). 2000, 289 (5482): 1197-1202.CrossRef
3.
Christian S, Ahorn H, Koehler A, Eisenhaber F, Rodi HP, Garin-Chesa P, Park JE, Rettig WJ, Lenter MC: Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. The Journal of biological chemistry. 2001, 276 (10): 7408-7414. 10.1074/jbc.M009604200.CrossRefPubMed
4.
Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proceedings of the National Academy of Sciences of the United States of America. 1992, 89 (22): 10832-10836. 10.1073/pnas.89.22.10832.CrossRefPubMedPubMedCentral
5.
Simonavicius N, Robertson D, Bax DA, Jones C, Huijbers IJ, Isacke CM: Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol. 2008, 21 (3): 308-315. 10.1038/modpathol.3801006.CrossRefPubMed
6.
Davies G, Cunnick GH, Mansel RE, Mason MD, Jiang WG: Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clinical & experimental metastasis. 2004, 21 (1): 31-37. 10.1023/B:CLIN.0000017168.83616.d0.CrossRef
7.
Brady J, Neal J, Sadakar N, Gasque P: Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. Journal of neuropathology and experimental neurology. 2004, 63 (12): 1274-1283.CrossRefPubMed
8.
MacFadyen JR, Haworth O, Roberston D, Hardie D, Webster MT, Morris HR, Panico M, Sutton-Smith M, Dell A, Geer van der P, et al: Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS letters. 2005, 579 (12): 2569-2575. 10.1016/j.febslet.2005.03.071.CrossRefPubMed
9.
Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B: Cell surface tumor endothelial markers are conserved in mice and humans. Cancer research. 2001, 61 (18): 6649-6655.PubMed
10.
Christian S, Winkler R, Helfrich I, Boos AM, Besemfelder E, Schadendorf D, Augustin HG: Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. The American journal of pathology. 2008, 172 (2): 486-494. 10.2353/ajpath.2008.070623.CrossRefPubMedPubMedCentral
11.
Tomkowicz B, Rybinski K, Foley B, Ebel W, Kline B, Routhier E, Sass P, Nicolaides NC, Grasso L, Zhou Y: Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proceedings of the National Academy of Sciences of the United States of America. 2007, 104 (46): 17965-17970. 10.1073/pnas.0705647104.CrossRefPubMedPubMedCentral
12.
Becker R, Lenter MC, Vollkommer T, Boos AM, Pfaff D, Augustin HG, Christian S: Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K. Faseb J. 2008, 22 (8): 3059-3067. 10.1096/fj.07-101386.CrossRefPubMed
13.
Nanda A, Karim B, Peng Z, Liu G, Qiu W, Gan C, Vogelstein B, St Croix B, Kinzler KW, Huso DL: Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proceedings of the National Academy of Sciences of the United States of America. 2006, 103 (9): 3351-3356. 10.1073/pnas.0511306103.CrossRefPubMedPubMedCentral
14.
Carson-Walter EB, Hampton J, Shue E, Geynisman DM, Pillai PK, Sathanoori R, Madden SL, Hamilton RL, Walter KA: Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumor angiogenesis. Clin Cancer Res. 2005, 11 (21): 7643-7650. 10.1158/1078-0432.CCR-05-1099.CrossRefPubMed
15.
Nordfors K, Haapasalo J, Helen P, Paetau A, Paljarvi L, Kalimo H, Kinnula VL, Soini Y, Haapasalo H: Peroxiredoxins and antioxidant enzymes in pilocytic astrocytomas. Clinical neuropathology. 2007, 26 (5): 210-218.CrossRefPubMed
16.
Shue EH, Carson-Walter EB, Liu Y, Winans BN, Ali ZS, Chen J, Walter KA: Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models. BMC neuroscience. 2008, 9: 29-10.1186/1471-2202-9-29.CrossRefPubMedPubMedCentral
17.
Bagley RG, Weber W, Rouleau C, Yao M, Honma N, Kataoka S, Ishida I, Roberts BL, Teicher BA: Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. International journal of oncology. 2009, 34 (3): 619-627. 10.3892/ijo_00000187.CrossRefPubMed
18.
Bagley RG, Honma N, Weber W, Boutin P, Rouleau C, Shankara S, Kataoka S, Ishida I, Roberts BL, Teicher BA: Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Microvascular research. 2008, 79 (3): 180-188. 10.1016/j.mvr.2008.07.008.CrossRef
19.
MacFadyen J, Savage K, Wienke D, Isacke CM: Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development. Gene Expr Patterns. 2007, 7 (3): 363-369. 10.1016/j.modgep.2006.07.006.CrossRefPubMed
20.
Bagley RG, Rouleau C, St Martin T, Boutin P, Weber W, Ruzek M, Honma N, Nacht M, Shankara S, Kataoka S, et al: Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248. Molecular cancer therapeutics. 2008, 7 (8): 2536-2546. 10.1158/1535-7163.MCT-08-0050.CrossRefPubMed
21.
Rouleau C, Curiel M, Weber W, Smale R, Kurtzberg L, Mascarello J, Berger C, Wallar G, Bagley R, Honma N, et al: Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res. 2008, 14 (22): 7223-7236. 10.1158/1078-0432.CCR-08-0499.CrossRefPubMed
22.
Conejo-Garcia JR, Buckanovich RJ, Benencia F, Courreges MC, Rubin SC, Carroll RG, Coukos G: Vascular leukocytes contribute to tumor vascularization. Blood. 2005, 105 (2): 679-681. 10.1182/blood-2004-05-1906.CrossRefPubMed
23.
Tentori L, Vergati M, Muzi A, Levati L, Ruffini F, Forini O, Vernole P, Lacal PM, Graziani G: Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. International journal of oncology. 2005, 27 (2): 525-535.PubMed
24.
Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. The Journal of clinical investigation. 2003, 111 (9): 1287-1295.CrossRefPubMedPubMedCentral
25.
Cao Y, Sonveaux P, Liu S, Zhao Y, Mi J, Clary BM, Li CY, Kontos CD, Dewhirst MW: Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer research. 2007, 67 (8): 3835-3844. 10.1158/0008-5472.CAN-06-4056.CrossRefPubMed
26.
Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA: Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer research. 2006, 66 (18): 9054-9064. 10.1158/0008-5472.CAN-05-3759.CrossRefPubMed
27.
Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005, 121 (3): 335-348. 10.1016/j.cell.2005.02.034.CrossRefPubMed
28.
Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R: Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer research. 2007, 67 (21): 10123-10128. 10.1158/0008-5472.CAN-07-3127.CrossRefPubMed
29.
Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, et al: Long-term survival with glioblastoma multiforme. Brain. 2007, 130 (Pt 10): 2596-2606. 10.1093/brain/awm204.CrossRefPubMed
30.
Virgintino D, Girolamo F, Errede M, Capobianco C, Robertson D, Stallcup WB, Perris R, Roncali L: An intimate interplay between precocious, migrating pericytes and endothelial cells governs human fetal brain angiogenesis. Angiogenesis. 2007, 10 (1): 35-45. 10.1007/s10456-006-9061-x.CrossRefPubMed
31.
Camphausen K, Purow B, Sproull M, Scott T, Ozawa T, Deen DF, Tofilon PJ: Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proceedings of the National Academy of Sciences of the United States of America. 2005, 102 (23): 8287-8292. 10.1073/pnas.0502887102.CrossRefPubMedPubMedCentral
32.
Ohradanova A, Gradin K, Barathova M, Zatovicova M, Holotnakova T, Kopacek J, Parkkila S, Poellinger L, Pastorekova S, Pastorek J: Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2. British journal of cancer. 2008, 99 (8): 1348-1356. 10.1038/sj.bjc.6604685.CrossRefPubMedPubMedCentral
33.
Marty C, Langer-Machova Z, Sigrist S, Schott H, Schwendener RA, Ballmer-Hofer K: Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer letters. 2006, 235 (2): 298-308. 10.1016/j.canlet.2005.04.029.CrossRefPubMed
Metadata
Title
Characterization of TEM1/endosialinin human and murine brain tumors
Authors
Eleanor B Carson-Walter
Bethany N Winans
Melissa C Whiteman
Yang Liu
Sally Jarvela
Hannu Haapasalo
Betty M Tyler
David L Huso
Mahlon D Johnson
Kevin A Walter
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-417

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma

Research article

Groucho binds two conserved regions of LEF-1 for HDAC-dependent repression

Research article

Differential expression of follistatin and FLRG in human breast proliferative disorders

Research article

Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran

Research article

Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: A population based case-control study

Research article

The incidence and risk of developing a second primary esophageal cancer in patients with oral and pharyngeal carcinoma: a population-based study in Taiwan over a 25 year period
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits